Welcome to our dedicated page for HSKA news (Ticker: HSKA), a resource for investors and traders seeking the latest updates and insights on HSKA stock.
Heska Corporation (NASDAQ: HSKA) is a leading provider of advanced veterinary diagnostic and imaging solutions. The company is dedicated to enhancing the quality of pet care through cutting-edge technology and comprehensive services. Founded by veterinary professionals for veterinary professionals, Heska is committed to upholding sound science and best medical practices.
Core Areas of Expertise:
- Diagnostic Systems: Heska offers state-of-the-art chemistry, hematology, and blood gas & electrolyte systems designed to deliver precise and reliable results.
- Imaging Solutions: The company leads the field with advanced HD digital radiography, digital ultrasound, and PACS imaging technologies from Cuattro, facilitating more accurate diagnoses and effective treatments.
- Allergy & Renal Health: Heska provides specialized diagnostics for heartworm, early renal healthscreens, and comprehensive allergy testing and treatment options.
Headquartered in Loveland, Colorado, Heska serves veterinary practices worldwide, helping them improve patient care, productivity, and profitability. The company is known for its innovative products that meet the evolving needs of veterinary professionals.
Recent Achievements:
- Heska's partnership with Dalan Animal Health, Inc. to further expand their diagnostic capabilities.
- Introduction of new products aimed at enhancing diagnostic accuracy and efficiency in veterinary practices.
With a focus on excellence and a pledge to support veterinary practices, Heska continues to make significant strides in pet healthcare technology.
Heska Corporation (NASDAQ: HSKA) reported a Q1 2022 revenue of $64.8 million, a 7.1% increase year-over-year, with a consolidated gross margin up 290 bps to 45.0%. North America revenue grew slightly by 0.3%, while international revenue surged 18.1%. The company recorded a net loss of $10.0 million and an adjusted EBITDA margin of 11.9%. Key developments include the progress of the Heska Nu.Q® Vet Cancer Screen Test and a focus on point of care diagnostics. Despite the macroeconomic backdrop, Heska expects a full-year growth of at least 13%, with North America consumables projected to grow by 15% or more.
Heska Corporation (NASDAQ: HSKA), a leader in veterinary diagnostics, will host its 2022 Investor Day virtually on May 17, 2022, at 9:00 a.m. MT. Leadership will provide updates on the company's strategic plan for 2023-2027, its position in the global veterinary health market, and new products and services. The event will conclude with a Q&A session. Interested parties can register online to access the webcast, with presentations also available on the company’s investor relations site.
Heska Corporation (NASDAQ: HSKA) will announce its first quarter 2022 financial results on May 9, 2022, before market opening. An earnings call is scheduled for 9 a.m. MT / 11 a.m. ET to discuss the outcomes. The company, specialized in veterinary diagnostics and healthcare solutions, operates in North America and International markets. The earnings call will be accessible via telephonic dial-in and webcast options. A replay will be available shortly after the call.
Heska Corporation (NASDAQ: HSKA) announced its 2022 Annual Meeting of Stockholders, scheduled for May 4, 2022, at 9 a.m. MT / 11 a.m. ET. Stockholders of record as of March 7, 2022, can participate and vote. The meeting will be virtual, and all stockholders are encouraged to vote on proposed matters via proxy as outlined in the proxy materials. A webcast of the meeting will be available, with a replay archived for 90 days on the company's website.
Heska Corporation (NASDAQ: HSKA) has entered an exclusive global supply and licensing agreement with VolitionRx Limited (NYSE AMERICAN: VNRX) to commercialize the Nu.Q® Vet Cancer Screening Test for companion animals. This test aims to provide veterinarians with the ability to screen pets for cancer at the point of care. With an estimated $11 billion market for canine and feline cancer screening, this innovative solution is expected to greatly enhance early detection and treatment for pets, benefiting both healthcare outcomes and pet owners.
Heska Corporation (NASDAQ: HSKA) reported strong financial results for the fourth quarter and full year of 2021, with consolidated revenue rising 28.6% to $253.7 million. Active subscriptions grew by 25%, and significant increases in North America (21.5%) and international (42.2%) sales of POC Lab Consumables were noted. The company expects 2022 revenue growth of 13-17%. Consolidated gross margins improved by 50 bps, reaching 41.7%. Heska remains optimistic about future growth, attributing their success to strategic initiatives and a strong position in the veterinary diagnostics market.
Heska Corporation (NASDAQ: HSKA) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, before market open. An earnings call is scheduled at 9 a.m. MT / 11 a.m. ET to discuss the results. The call can be accessed via phone and will also be webcast live on the company’s investor relations site. A replay will be available from 2 p.m. ET on February 28 through March 14, 2022. Heska manufactures advanced veterinary diagnostic products across North America and internationally.
Heska Corporation (NASDAQ: HSKA) has successfully completed the acquisition of VetZ GmbH, a leader in veterinary practice information management software based in Germany. Announced on November 2, 2021, this acquisition marks a pivotal step in Heska's strategic growth plan. VetZ, known for its integrated software solutions enhancing veterinary workflows and patient care since 1997, is expected to significantly bolster Heska's market position in Europe. Further insights and details regarding the acquisition will be shared during Heska's Q4 and full-year 2021 financial report in February 2022.
Heska Corporation (NASDAQ: HSKA) announced that its President & CEO, Kevin Wilson, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 p.m. ET. The presentation will be available live for registered attendees and an audio-only version will be accessible to the public. A replay will be available for 90 days after the event. Additionally, Mr. Wilson and the management team will hold one-on-one meetings with investors on the same day. For more details, visit the J.P. Morgan Health Care Conference Website.
Heska Corporation (NASDAQ: HSKA) reported Q3 2021 revenues of $60.2 million, up 6.4% year-over-year. North America revenue rose 9.8% to $37.8 million, driven by 10.1% growth in Point of Care Lab Consumables and 41.1% in Imaging. However, the company faced a net loss of $1.9 million, a 63.6% increase from the prior year. Adjusted EBITDA decreased 34.8% to $5.6 million, with operating margins declining due to $4.5 million in increased expenses. Liquidity remains strong with $222.9 million in cash. Recent acquisitions aim to enhance product offerings.
FAQ
What is the market cap of HSKA (HSKA)?
What does Heska Corporation specialize in?
Where is Heska Corporation headquartered?
Who founded Heska Corporation?
What are Heska’s main products?
What recent achievements has Heska Corporation made?
How does Heska support veterinary practices?
What sets Heska apart from other veterinary diagnostic companies?
What types of diagnostic systems does Heska offer?
What imaging technologies does Heska provide?
How does Heska ensure the quality of its products?
